scholarly journals Biomarker Use in Colorectal Cancer Therapy

2011 ◽  
Vol 9 (11) ◽  
pp. 1293-1302 ◽  
Author(s):  
Robin K. Kelley ◽  
Grace Wang ◽  
Alan P. Venook
Keyword(s):  
Colorectal Cancer ◽  
Clinical Management ◽  
Mutational Analysis ◽  
Colorectal Cancers ◽  
Repair Protein ◽  
Established Role ◽  
Case Based ◽  
Mismatch Repair Protein ◽  
Selection Of ◽  
Novel Therapeutic

Biomarkers reflective of the molecular and genetic heterogeneity in colorectal cancers now guide certain aspects of clinical management and offer great potential for enrichment, stratification, and identification of novel therapeutic targets in drug development. Using case-based examples, this article reviews biomarkers that have an established role in the clinical management of colorectal cancer: mismatch repair protein testing and KRAS and BRAF mutational analysis. A selection of biomarkers undergoing validation for future clinical application is presented, and the dynamic and challenging interface between biomarkers in research and clinical practice is discussed.

scholarly journals Lack of DNA mismatch repair protein MSH6 in the rat results in hereditary non-polyposis colorectal cancer-like tumorigenesis

2008 ◽  
Vol 29 (6) ◽  
pp. 1290-1297 ◽  
Author(s):  
Ruben van Boxtel ◽  
Pim W. Toonen ◽  
Henk S. van Roekel ◽  
Mark Verheul ◽  
Bart M. G. Smits ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mismatch Repair ◽  
Dna Mismatch Repair ◽  
Dna Mismatch ◽  
Repair Protein ◽  
Mismatch Repair Protein

Mismatch repair protein MSH2 expression and prognosis of colorectal cancer patients

2004 ◽  
Vol 19 (3) ◽  
pp. 190-195
Author(s):  
C.G. Bernardo ◽  
J.J. Gonzalez ◽  
L. Sanz ◽  
E. Barbn ◽  
J.G. Noval ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Mismatch Repair ◽  
Repair Protein ◽  
Colorectal Cancer Patients ◽  
Mismatch Repair Protein

Mismatch Repair Protein MSH2 Expression and Prognosis of Colorectal Cancer Patients

2004 ◽  
Vol 19 (3) ◽  
pp. 190-195 ◽  
Author(s):  
C.G. Bernardo ◽  
J.J. Gonzílez ◽  
L. Sanz ◽  
E. Barbón ◽  
J.G. Noval ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Vascular Invasion ◽  
Sporadic Colorectal Cancer ◽  
Repair Protein ◽  
N Stage ◽  
Colorectal Cancer Patients ◽  
Mismatch Repair Protein

Introduction and aims The role of genetic factors in the etiology and prognosis of patients with sporadic colorectal cancer is controversial. We have therefore investigated the biological and clinicopathological influence of immunohistochemical MSH2 expression in colorectal cancer. Patients and methods A total of 49 consecutive patients with unselected colorectal cancer operated on in our unit were included in the study. All tumors were resected and tumor specimens were evaluated for MSH2 expression. Clinicopathological data and patient survival were correlated with MSH2 staining. Uni- and multivariate analyses were performed. The minimum follow-up period was five years. Results Curative resection was performed in 34 patients (64.9%), 14 of whom subsequently relapsed. At the end of the overall follow-up 25 (51%) patients had died, 21 of cancer-related causes. Twenty-eight patients (57.1%) were negative for MSH2 staining. Only vascular invasion was significantly correlated with MSH2 expression (lower median values; p=0.04). The overall median survival was 47.9 months (95% CI=27–86.6%). Multivariate analysis of variables in relation to survival showed that T stage (p=0.001), N stage (p<0.001) and MSH2 expression (p=0.01) were independent factors for survival. Conclusions Reduced MSH2 expression is frequent in unselected colorectal cancer patients. Only vascular invasion was correlated with MSH2 expression in this study. Survival was related to TN stage and MSH2 staining.

Sign in / Sign up

Export Citation Format

Share Document